This site is intended for healthcare professionals
Drug news

EU approves Xofigo (Bayer) for Prostate Cancer

Read time: 1 mins
Last updated:17th Nov 2013
Published:17th Nov 2013
Source: Pharmawand

Bayer HealthCare announced that the European Commission (EC) on 15 November 2013 has granted marketing authorisation for Xofigo 1000 kBq/ml, solution for injection (radium Ra 223 dichloride) for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. The approval of Xofigo is based on data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights